<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=629540654941475&amp;ev=PageView&amp;noscript=1">
Skip to content

Driving Innovation in

Biomarker Development

for Brain Health

BrainScope is helping to shape the future of brain disorder assessment and treatment optimization through advanced biomarker development powered by brain electrical activity (EEG).



We are committed to developing novel biomarkers that provide unprecedented insights into the brain, in a way that is not only faster, less expensive, and more accessible than the current standards, but also sensitive to the earliest signs of dysfunction, before structural damage occurs.

vecteezy_conceptual-3d-animation-of-digital-brain-hologram-with-ai_11591321
Icon PRECISION FOR CNS DRUG DEVELOPMENT

Optimizing

Clinical Trials

BrainScope’s Large Neural Model Platform has the potential to significantly impact clinical trials, particularly in the complex and costly field of CNS drug development. By applying BrainScope's AI model to EEG data acquired from any source, we can aid in transforming how brain conditions are assessed and managed.

pexels-mikhail-nilov-8851446 1
Detect and Segment Disease
Detect and Segment Disease

helping identify brain dysfunction and disease subtype through an unbiased, data-driven approach

Predict Treatment Outcomes
Predict Treatment Outcomes

helping to reduce costs and failure rates by forecasting patient response and improving trial design

Streamline Patient Selection
Streamline Patient Selection

helping to maximize ability to choose the right participants for the right trials

Enhance Trial Design
Enhance Trial Design

helping to minimize off-target effects and maximize trial power

Icon FROM EEG SIGNALS TO ACTIONABLE BIOMARKERS

The Vision for the Future

Backed by substantial evidence of EEG's effectiveness in CNS disorders alongside BrainScope's formidable portfolio of patents, technology, data, and know-how, BrainScope biomarker innovations have the potential to revolutionize early diagnosis, monitoring, treatment prediction and outcome. We invite you to join us in pushing the boundaries of neuroscience and creating a healthier future.
ABOUT US
Icon MULTI-INDICATION UTILITY

Broad Impact for Brain Health

BrainScope's new biomarker development covers a range of critical brain health challenges, including early Alzheimer's prediction, sub-typing CNS diseases and rapid stroke assessment.
 
Background (1)
BrainScope's FDA-cleared biomarker for traumatically induced brain bleed assessment has also demonstrated utility for rapid stroke assessment (not FDA-cleared). Results of this retrospective study were published in the peer-reviewed journal Academic Emergency Medicine.
LEARN MORE 🡲
Background (2)
BrainScope also successfully developed a proof-of-concept biomarker for the prediction of onset of Alzheimer’s disease at its earliest stage in normal elderly individuals with memory complaints. This breakthrough was supported by an investment from ADDF.
LEARN MORE 🡲